IsoPlexis completes $25 million series C financing
IsoPlexis has raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
IsoPlexis has raised $25 million in Series C funding. The round was led by Northpond Ventures and included new strategic investment along with current investors...
While cases of syphilis in Europe were first recorded over 500 years ago, no vaccine candidates have ever advanced to human clinical trials. A new...
NextCure announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share....
Trevi Therapeutics has gone public, selling 5.5 million shares at $10 a share and raising $55 million. The company, which is developing a drug for...
SpringWorks Therapeutics reports that the first patient has been dosed in a Phase 1b study to evaluate the combination of SpringWorks Therapeutics’ investigational MEK inhibitor,...
Yale-New Haven Hospital has unveiled plans to build up its St. Raphael campus with a 505,000-square foot, $838 million neuroscience center for research and treatment...
KPMG LLP provides tax, audit and advisory services (including strategy, risk, regulatory and M&A) to over 500 life sciences clients in the northeast region. The...
A paper published in Nature Communications delves deeper into individual genomic differences than ever before. The work involved a large international team of researchers from the...
At April 29, the share price of BioXcel was 46% higher than it was a year before, much better than the market return of around...
Alexion Pharmaceuticals reports that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS®...